李迎红   有机化学室   副研究员   硕士生导师

教育背景及工作经历：

2004/09－2009/06 北京协和医学院 微生物与生化药学 博士

1999/09－2004/06 沈阳药科大学 药学英语 学士

2014/09－至今 中国医学科学院医药生物技术研究所 副研究员

2010/09－2012/09 South Dakota State University, Department of Pharmacy, Postdoc

2009/09－2014/09 中国医学科学院医药生物技术研究所 助理研究员

主要研究方向：抗菌和抗肿瘤药物的药物化学与化学生物学

专业研究领域：药物化学和化学生物学。一方面致力于对我国喹诺里西啶类生物碱天然产物，如苦参碱和苦豆碱等进行理性结构修饰与优化，从中寻找抗肿瘤创新药物候选物，并阐明其生物活性、化学生物学机制与化学基础。另一方面开展抗菌药物的化学生物学研究，通过化学生物学手段解释现有抗菌药物的耐药机制，从而寻找新型抗菌药物候选物。

代表性论文：

1. Zeng Q#, Deng H#, Li Y#, Fan T, Liu Y, Tang S, Wei W, Liu X, Guo X, Jiang J, Wang Y*, Song D*. Berberine Directly Targets the NEK7 Protein to Block the NEK7-NLRP3 Interaction and Exert Anti-inflammatory Activity. J Med Chem. 2021 Jan 14;64(1):768-781.

2. Fan T†, Ge M†, Guo Z, He H, Zhang N*, Li Y*, Song D. Discovery of 9O-Substituted Palmatine Derivatives as a New Class of anti-COL1A1 Agents via Repressing TGF-β1/Smads and JAK1/STAT3 Pathways. Molecules 2020, 25(4):773.

3. Wang K, Guo Z, Bao Y, Pang Y, Li Y*, He H*, Song D. Structure-Activity Relationship of Aloperine Derivatives as New Anti-Liver Fibrogenic Agents. Molecules 2020, 25(21): 4977.

4. Zhang D, Zhang X, Li Z, Tang S, Guo Z, Hu C, Zhang J, Song D, Li Y#. Comprehensive 2D-Quantitative Structure-Activity Relationship Study on Monobactam Analogues Against Gram-Negative Bacteria. J. Biomed. Nanotechnol. 2020,16, 941–953.

5.Liu T, Zeng Q, Zhao X,Wei W, Li Y*, Deng H*, Song D. Synthesis and Biological Evaluation of Fangchinoline Derivatives as Anti-Inflammatory Agents through Inactivation of Inflammasome. Molecules 2019, 24(6):1154.

6. Tang S†, Li Y†, Bao Y, Dai Z, Niu T, Wang K, He H*, Song D*. Novel cytisine derivatives exert anti-liver fibrosis effect via PI3K/Akt/Smad pathway. Bioorg Chem. 2019 Sep;90:103032.

7. Bao Y†, Pang Y†, Tang S, Niu T, Guo Z, He H*, Li Y*, Song D. 12N-Substituted Matrinol Derivatives Inhibited the Expression of Fibrogenic Genes via Repressing Integrin/FAK/PI3K/Akt Pathway in Hepatic Stellate Cells. Molecules 2019, 24, 3748.

8. Fan T†, Hu X†, Tang S, Liu X, Wang Y, Deng H, You X, Jiang J, Li Y*, Song D*. Discovery and Development of 8-Substituted Cycloberberine Derivatives as Novel Antibacterial Agents against MRSA. ACS Med Chem Lett. 2018, 9(5):484-489.

9. Niu T†, Niu W†, Bao Y, Liu T, Song D, Li Y*, He H*. Discovery of Matrinic Thiadiazole Derivatives as a Novel Family of Anti-Liver Fibrosis Agents via Repression of the TGFβ/Smad Pathway. Molecules 2018, 23(7): E1644.

10. Cheng XY†, Li YH†, Tang S, Zhang X, Wang YX, Wang SG, Jiang JD, Li YH*, Song DQ*. Synthesis and evaluation of halogenated 12N-sulfonyl matrinic butanes as potential anti-coxsackievirus agents. Eur J Med Chem. 2017, 126:133-142.

11. Li YH†, Wu ZY†, Tang S, Zhang X, Wang YX, Jiang JD, Peng ZG*, Song DQ*. Evolution of matrinic ethanol derivatives as anti-HCV agents from matrine skeleton. Bioorg Med Chem Lett. 2017, 27(9): 1962-1966.

12. Li YH†, Tang S†, Li YH, Cheng XY, Zhang X, Wang YX, Su F*, Song DQ*. Novel 12N-substituted matrinanes as potential anti-coxsackievirus agents. Bioorg Med Chem Lett. 2017, 27(4): 829-833.

13. Li Y, Peng Z, Gao L, Song D*. Synthesis and biological evaluation of sophocarpinic acid derivatives as anti-HCV agents, Acta Pharmaceutica Sinica B 2014, 4(4):307-312.

14. Li Y, Liu Y, Wang Y, Tang S, Song D*. Synthesis and biological evaluation of new 13-n-nonylprotoberberine derivatives as antitubercular agents. Acta Pharmaceutica Sinica B 2013, 3(1): 38-45.

15. Li YH†, Fu HG†, Su F, Gao LM, Tang S, Bi CW, Li YH, Wang YX*, Song DQ*. Synthesis and structure-activity relationship of 8-substituted protoberberine derivatives as a novel class of antitubercular agents. Chem Cent J. 2013, 7(1): 117.

16. Li Y, Yang Y, Guan X*. Benzofurazan sulfides for thiol imaging and quantification in live cells through fluorescence microscopy, Anal Chem. 2012.8.7, 84(15): 6877-6883.

17. Li YH†, Li Y†, Yang P, Kong WJ, You XF, Ren G, Deng HB, Wang YM, Wang YX, Jiang JD*, Song DQ*. Design, synthesis, and cholesterol-lowering efficacy for prodrugs of berberrubine. Bioorg Med Chem. 2010, 18(17): 6422-6428.

18. Li YH†, Yang P†, Kong WJ†, Wang YX, Hu CQ, Zuo ZY, Wang YM, Gao H, Gao LM, Feng YC, Du NN, Liu Y, Song DQ*, Jiang JD*. Berberine analogues as a novel class of the low-density-lipoprotein receptor up-regulators: synthesis, structure-activity relationships, and cholesterol-lowering efficacy. J Med Chem. 2009, 52(2): 492-501.

专利：

1. 宋丹青;毕重文;李迎红;唐胜;范田运;蒋建东;邓洪斌;叶程. 槐定胺类衍生物及其制备方法和用途. 专利号: ZL201610130041.1, 授权日期：2021/04/23.

2. 宋丹青;唐胜;汪燕翔;孔维佳;李迎红;牛天宇;程新越. 取代苯磺酰苦参丁烷或其盐酸盐的制备方法, 专利号: ZL201710090231.X, 授权日期：2021/03/23.

3. 宋丹青;蒋建东;唐胜;孔维佳;汪燕翔;王灿;李迎红;李玉环;张靖浦. 苦参烷类衍生物的降血糖活性,专利号: ZL201710152735.X, 授权日期: 2020/9/11.

4. 宋丹青;李迎红;何红伟;牛天宇;唐胜;鲍云洋;庞雨东. 12N-取代胺甲酰基苦参碱衍生物及其制备方法和用途. 专利号: ZL201910144441.1, 授权日期: 2020/5/1.

5. 宋丹青;蒋建东;彭宗根;张欣;唐胜;李迎红;李玉环. 苦豆碱衍生物、其制备方法及用途. 专利号:ZL201510956338.9, 授权日期: 2019/12/18.

6. 宋丹青;邓洪斌;张欣;张靖溥;窦玥莹;唐胜;汪燕翔;李迎红;张娜. 苦豆碱衍生物在制备治疗肿瘤的药物中的应用. 专利号:ZL2017 1 0136438.6, 授权日期: 2019/9/3.

7. 宋丹青;李玉环;唐胜;李迎红;蒋建东;孔兰英;王圣刚. 苦参碱类化合物衍生物及其制备方法和用途. 专利号: ZL201510294256.2, 授权日期: 2018/11/13.

8. Xiangming GUAN;Chandrahar DWIVEDI;Yinghong LI;Yang YANG;John H. LEE;Wilson Keith MISKIMINS. Combination uses of dichloroacetate and oxamate, and their prodrugs, for cancer treatment. US14699946, patent date: 2017/01/31.

9. 宋丹青;邵荣光;毕重文;蒋建东;张彩霞;唐胜;李迎红. 新型槐定碱类衍生物槐定酸、槐定醇、槐定酯、槐定醚及其制备方法和用途. 专利号: CN201310268482.4, 授权日期:2016/10/12

专著：参编《小檗碱》，科学出版社，2018年11月.

获奖情况：

1. 2019年中国药学会科学技术二等奖

2. 2016年中国药学会科学技术二等奖

3. 第十三届中国药学会青年成果交流药学会二等奖， 2016年09月，南昌

4. 第九届世界药物化学会议优秀墙报奖，2014年08月，沈阳

5. 药生所第二十四届 “五四”青年论文“甄永苏青年科技奖”，2009年05月，北京

联系电话：010-63033012

电子邮箱： liyinghong@imb.pumc.edu.cn ; yinghongli523@aliyun.com.